1437304-93-2

Upstream product

• 195314-59-1 tert-butyl (4-aminocyclohexyl)carbamate 
• 621-29-4 3-tolyl isocyanate 
• 1445768-26-2 tert-butyl 4-(3-m-tolylureido)cyclohexylcarbamate 
• 3114-70-3 trans-1,4-diaminocyclohexane 
• 400784-50-1 4-hydroxy-5-chloro-8-nitro-quinazoline 
• 1155633-86-5 C₁₄H₂₁N₃O 

Relevant academic research and scientific papers

A [...] urea and its preparation and use

The invention discloses quinazoline arylurea compounds and a preparation method and an application thereof, wherein the quinazoline arylurea compounds have a general formula I. The new compound with quinazolinyl and aryl-substituted urea shows extremely high activity in suppressing the growth of tumor cells, and particularly realizes an obvious effect in suppressing the growth of VEGFR high-expression HUVEC cells, wherein half of the suppression IC50 values can reach 1.8 mu g/mL. The invention also provides a preparation method of the compounds.

Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: Synthesis, biological evaluation and molecular docking

Vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibition is a well-established strategy to promptly tackle tumor growth by suppression of angiogenesis. We report herein a series of 5-anilinoquinazoline derivatives substituted by 1,3-disubstituted urea. All the newly synthesized compounds described were evaluated for VEGFR-2 kinase inhibition and antiproliferative activity against various cancer cells. The novel 1-aryl, 3-aryl-disubstituted urea quinazolines were effective VEGFR-2 kinase inhibitors with in vitro IC 50 values in the submicromolar range (compound 6f, IC50 12.0 nM), but showed a weak to moderate inhibitory activity on cancer cells. Molecular interactions of the compounds were studied using molecular docking studies. The Royal Society of Chemistry 2013.